Cian Healthcare Valuation

Is 542678 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 542678 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 542678 (₹4.72) is trading below our estimate of fair value (₹72.88)

Significantly Below Fair Value: 542678 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 542678?

Key metric: As 542678 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 542678. This is calculated by dividing 542678's market cap by their current earnings.
What is 542678's PE Ratio?
PE Ratio	46.4x
Earnings	₹2.54m
Market Cap	₹117.98m

542678 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.1x
Enterprise Value/EBITDA	5.9x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 542678's PE Ratio compare to its peers?

The above table shows the PE ratio for 542678 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	29.1x
531210 Colinz Laboratories	27.6x	n/a	₹138.6m
543500 Evoq Remedies	40.2x	n/a	₹182.0m
524752 Decipher Labs	18.3x	n/a	₹152.4m
524400 Ishita Drugs and Industries	30.5x	n/a	₹226.5m
542678 Cian Healthcare	46.4x	n/a	₹118.0m

Price-To-Earnings vs Peers: 542678 is expensive based on its Price-To-Earnings Ratio (46.4x) compared to the peer average (29.1x).

Price to Earnings Ratio vs Industry

How does 542678's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap
INDSWFTLAB Ind-Swift Laboratories	1.6x	n/a	US$70.43m
524652 Ind-Swift	2x	n/a	US$13.12m

No more companies available in this PE range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 542678 is expensive based on its Price-To-Earnings Ratio (46.4x) compared to the Indian Pharmaceuticals industry average (31.6x).

Price to Earnings Ratio vs Fair Ratio

What is 542678's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

542678 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	46.4x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 542678's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Vilin Bio Med

₹293.6m

Engages in the manufacture and sale of pharmaceutical products in India.

VILINBIO

₹21.05

7.4%

-0.9%

Venus Remedies

₹3.9b

Engages in the pharmaceutical business in India and internationally.

VENUSREM

₹291.85

-3.6%

-22.2%

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹928.00

-1.7%

15.6%